Spots Global Cancer Trial Database for leukapheresis
Every month we try and update this database with for leukapheresis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | NCT02639559 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Non-Hodgkin's L... Non-Hodgkin Lym... Hodgkin Disease Hodgkins Diseas... Hodgkin's Disea... Multiple Myelom... Myelodysplastic... Myeloproliferat... | BL-8040 Leukapheresis Hematopoietic c... | 18 Years - 75 Years | Washington University School of Medicine | |
| Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia | NCT04881240 | Acute Lymphobla... Acute Lymphobla... Pediatric ALL | CD19-CAR(Mem) T... Cyclophosphamid... Fludarabine Mesna CliniMACS Leukapheresis | - 21 Years | St. Jude Children's Research Hospital | |
| Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | NCT03168438 | Neoplasms | Letetresgene au... Letetresgene au... Fludarabine Cyclophosphamid... Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | NCT01044069 | Leukemia Acute Lymphobla... | gene-modified T... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions | NCT03937791 | Squamous Lntrae... Neoplasms, Squa... Vulvar HSIL | E7 T Cell Recep... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma | NCT05801913 | High Grade B-Ce... Intermediate Gr... Recurrent B-Cel... Refractory B-Ce... | Anti-CD19-CAR C... Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Leukapheresis Lymphodepletion... Magnetic Resona... Multi-peptide C... Positron Emissi... X-Ray Imaging | 18 Years - | City of Hope Medical Center | |
| CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma | NCT03710421 | Recurrent Plasm... Refractory Plas... | CS1-CAR T Thera... Cyclophosphamid... Fludarabine Leukapheresis | 18 Years - | City of Hope Medical Center | |
| GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC) | NCT05003895 | Hepatocellular ... Hepatocellular ... Metastatic Hepa... | Cyclophosphamid... CAR-T cell Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors | NCT05672459 | Solid Tumor | Single Injectio... Fludarabine pho... Cyclophosphamid... leukapheresis | 18 Years - | M.D. Anderson Cancer Center | |
| Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab | NCT03709706 | Neoplasms | Lete-cel Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML | NCT04354025 | Refractory Acut... Relapsed Acute ... | Cytokine induce... Fludarabine Ara-C G-CSF Interleukin-2 Leukapheresis | 1 Year - 21 Years | Washington University School of Medicine | |
| Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma | NCT01045460 | Multiple Myelom... | Activated marro... Allogeneic Myel... Cyclophosphamid... Filgrastim Leukapheresis Melphalan Autologous stem... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | NCT00968760 | Lymphoma B-cell Lymphoma | Leukapheresis Stem Cell Trans... CD19-specific T... IL-2 Carmustine Etoposide Cytarabine Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma | NCT00566228 | Lymphoma | autologous hema... leukapheresis | 18 Years - 120 Years | Mayo Clinic | |
| CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT05950113 | Recurrent Multi... Refractory Mult... | Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Echocardiograph... Fludarabine Fludeoxyglucose... Immunotherapy Leukapheresis Magnetic Resona... Positron Emissi... | 18 Years - 74 Years | Jonsson Comprehensive Cancer Center | |
| A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas | NCT05773040 | Lymphomas B-cell Lymphoma... | JV-213 Leukapheresis | 18 Years - | M.D. Anderson Cancer Center | |
| Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | NCT03168438 | Neoplasms | Letetresgene au... Letetresgene au... Fludarabine Cyclophosphamid... Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer | NCT00020722 | Breast Cancer | therapeutic aut... Ifosfamide, car... Cyclophosphamid... Leukapheresis peripheral bloo... | 18 Years - 120 Years | Barbara Ann Karmanos Cancer Institute | |
| Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation | NCT02431988 | Diffuse Large B... | Leukapheresis Cyclophosphamid... Fludarabine CAR19 T-Cells | 16 Years - 65 Years | University College, London | |
| Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations | NCT06043713 | Metastatic Colo... Metastatic Lung... Metastatic Panc... Stage IV Colore... Stage IV Lung C... Stage IV Pancre... | Bendamustine Biopsy Biospecimen Col... Computed Tomogr... Cyclophosphamid... Echocardiograph... Fludarabine Leukapheresis Magnetic Resona... Multigated Acqu... Positron Emissi... T-cell Receptor... | 18 Years - | Fred Hutchinson Cancer Center | |
| Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | NCT01808820 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... High Grade Glio... | Dendritic Cell ... Tumor Lysate Imiquimod Leukapheresis | 13 Years - 99 Years | University of Miami | |
| Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | NCT01898793 | Leukemia, Myelo... | Fludarabine Cyclophosphamid... Leukapheresis Cytokine-induce... IL-2 ALT-803 Peripheral bloo... Bone marrow for... | 2 Years - | Washington University School of Medicine | |
| Study of Mast Cell Precursors | NCT00001756 | Mastocytosis Healthy Volunte... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | ||
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | NCT03277729 | Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent... | Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho... | 18 Years - | Fred Hutchinson Cancer Center | |
| Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy | NCT06435351 | Breast Cancer Triple Negative... | Leukapheresis Dendritic Cell ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Dendritic Cell Vaccine for Children and Adults With Sarcoma | NCT01803152 | Sarcoma Soft Tissue Sar... Bone Sarcoma | Dendritic Cells... Lysate of Tumor Gemcitabine Imiquimod Leukapheresis | 1 Year - 100 Years | University of Miami | |
| GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC) | NCT05003895 | Hepatocellular ... Hepatocellular ... Metastatic Hepa... | Cyclophosphamid... CAR-T cell Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission | NCT05707273 | B Acute Lymphob... | Autologous Anti... Biospecimen Col... Bone Marrow Asp... Cyclophosphamid... Fludarabine Leukapheresis Questionnaire A... | 55 Years - | City of Hope Medical Center | |
| Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | NCT05873712 | Recurrent Trans... Refractory Tran... Transformed Chr... Recurrent Trans... Recurrent Trans... Refractory Tran... Refractory Tran... Refractory Tran... | Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Fludarabine Leukapheresis Lisocabtagene M... Lymph Node Biop... Positron Emissi... Zanubrutinib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer | NCT03166254 | Non Small Cell ... NSCLC Non-small Cell ... Small Cell Lung... | Pembrolizumab NEO-PV-01 vacci... Biopsy Poly ICLC Leukapheresis Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma | NCT02728531 | Mantle Cell Lym... | Bendamustine Rituximab Cytarabine Pegfilgrastim Leukapheresis Filgrastim Autologous stem... | 18 Years - 65 Years | Washington University School of Medicine | |
| Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | NCT06094842 | Prostate Carcin... Prostate Small ... Stage III Prost... Stage IV Prosta... | Bendamustine Biopsy Biospecimen Col... Bone Scan Bridge Therapy Computed Tomogr... Cyclophosphamid... Echocardiograph... Fludarabine Leukapheresis Multigated Acqu... T-cell Receptor... X-Ray Imaging | 18 Years - | Fred Hutchinson Cancer Center | |
| Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | NCT01808820 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... High Grade Glio... | Dendritic Cell ... Tumor Lysate Imiquimod Leukapheresis | 13 Years - 99 Years | University of Miami | |
| Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | NCT03623373 | Mantle Cell Lym... | Bendamustine Rituximab Acalabrutinib Cytarabine Leukapheresis Peripheral bloo... Oral rinse Bone marrow col... | 18 Years - 70 Years | Washington University School of Medicine | |
| Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally | NCT00083538 | Multiple Myelom... | Dexamethasone Thalidomide Cisplatinum Adriamycin Cyclophosphamid... Etoposide | 18 Years - | University of Arkansas | |
| Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients. | NCT05835726 | Multiple Myelom... Daratumumab Autologous Stem... Leukapheresis | Daratumumab | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma | NCT05800405 | Recurrent Diffu... Refractory Diff... | Biospecimen Col... Chimeric Antige... Computed Tomogr... External Beam R... Leukapheresis Magnetic Resona... Positron Emissi... | 18 Years - | City of Hope Medical Center | |
| Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells | NCT01783431 | Melanoma | Poly ICLC leukapheresis | 18 Years - | Medical University of South Carolina | |
| Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | NCT01087294 | Leukemia, B-cel... Lymphoma, Hodgk... Lymphoma, Non-h... Lymphoma, B-Cel... | Allogeneic stem... Anti-CD19-chime... Leukapheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation | NCT00363467 | Acute Myeloid L... | G-CSF Leukapheresis Busulfan Stem cell reinf... | 56 Years - 74 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma | NCT03506802 | HLA-A*0201 Posi... NY-ESO-1 Positi... Recurrent Plasm... Refractory Plas... | 18F-FHBG Aldesleukin Cellular Therap... Computed Tomogr... Filgrastim Laboratory Biom... Lenalidomide Leukapheresis Melphalan Plerixafor Positron Emissi... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| A Phase I Trial of Anti-GD2 T-cells (1RG-CART) | NCT02761915 | Relapsed or Ref... | Leukapheresis Cyclophosphamid... Fludarabine 1RG-CART | 1 Year - | Cancer Research UK | |
| Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | NCT03168438 | Neoplasms | Letetresgene au... Letetresgene au... Fludarabine Cyclophosphamid... Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells | NCT06186401 | EGFR Gene Mutat... Glioblastoma MGMT-Unmethylat... Recurrent Gliob... | E-SYNC T Cells Cyclophosphamid... Fludarabine (no... Leukapheresis Surgical resect... | 18 Years - | University of California, San Francisco | |
| Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma | NCT03121677 | Follicular Lymp... | Personalized tu... Poly ICLC Nivolumab Peripheral bloo... Leukapheresis Rituximab Biopsy | 18 Years - | Washington University School of Medicine | |
| Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer | NCT05539365 | Anatomic Stage ... Anatomic Stage ... Metastatic Trip... Unresectable Tr... | Alpha-type-1 Po... Biopsy Computed Tomogr... Leukapheresis Pembrolizumab Quality-of-Life... | 18 Years - | Roswell Park Cancer Institute | |
| T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer | NCT03318900 | COL6A3 Positive HLA-A*0201 Posi... PRAME Positive Recurrent Ovari... | Aldesleukin CD8-Positive T-... Cyclophosphamid... Leukapheresis Utomilumab | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells | NCT01097057 | Non-Hodgkin Lym... | Carboplatin Etoposide Filgrastim Ifosfamide Leukapheresis Plerixafor Rituximab | 18 Years - | Fred Hutchinson Cancer Center | |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | NCT03277729 | Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent... | Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho... | 18 Years - | Fred Hutchinson Cancer Center | |
| Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors | NCT04665076 | Plasma Cell Tum... | Auto CAR-T Cyclophosphamid... Leukapheresis | 14 Years - 75 Years | Hebei Senlang Biotechnology Inc., Ltd. | |
| Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children | NCT04610125 | Leukemia Lymphoma | Auto CAR-T Cyclophosphamid... Leukapheresis | 1 Year - 18 Years | Hebei Senlang Biotechnology Inc., Ltd. | |
| Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab | NCT01416974 | Leukemia | cyclophosphamid... modified T cell... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine | NCT00861406 | Melanoma | Pegylated Inter... GP-100 Peptide ... | 18 Years - | M.D. Anderson Cancer Center | |
| Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant | NCT05457959 | Diffuse Hemisph... | Dendritic Cell ... Ipilimumab Leukapheresis Nivolumab Placebo Adminis... Placebo Adminis... Poly ICLC Resection | 13 Years - 60 Years | Jonsson Comprehensive Cancer Center | |
| Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer | NCT00020722 | Breast Cancer | therapeutic aut... Ifosfamide, car... Cyclophosphamid... Leukapheresis peripheral bloo... | 18 Years - 120 Years | Barbara Ann Karmanos Cancer Institute | |
| Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT02570542 | Diffuse Large B... Relapsed Diffus... Refractory Diff... | leukapheresis Plerixafor carmustine, eto... Autologous Stem... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia | NCT04881240 | Acute Lymphobla... Acute Lymphobla... Pediatric ALL | CD19-CAR(Mem) T... Cyclophosphamid... Fludarabine Mesna CliniMACS Leukapheresis | - 21 Years | St. Jude Children's Research Hospital | |
| Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab | NCT01416974 | Leukemia | cyclophosphamid... modified T cell... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children | NCT04610125 | Leukemia Lymphoma | Auto CAR-T Cyclophosphamid... Leukapheresis | 1 Year - 18 Years | Hebei Senlang Biotechnology Inc., Ltd. | |
| Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors | NCT01902771 | Glioma Brain Cancer Brain Tumor Glioblastoma Mu... High Grade Glio... | Dendritic Cell ... Tumor Lysate Imiquimod Leukapheresis | 1 Year - 29 Years | University of Miami | |
| Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally | NCT00083538 | Multiple Myelom... | Dexamethasone Thalidomide Cisplatinum Adriamycin Cyclophosphamid... Etoposide | 18 Years - | University of Arkansas | |
| Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma | NCT05800405 | Recurrent Diffu... Refractory Diff... | Biospecimen Col... Chimeric Antige... Computed Tomogr... External Beam R... Leukapheresis Magnetic Resona... Positron Emissi... | 18 Years - | City of Hope Medical Center | |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | NCT03277729 | Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent... | Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho... | 18 Years - | Fred Hutchinson Cancer Center | |
| A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma | NCT06342908 | Diffuse Hemisph... | Biospecimen Col... Dendritic Cell ... Leukapheresis Magnetic Resona... Poly ICLC | 18 Years - 50 Years | Jonsson Comprehensive Cancer Center | |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | NCT04981119 | Solid Tumor, Ad... Colorectal Canc... Non Small Cell ... Pancreatic Canc... CRC NSCLC Pancreas Cancer Mesothelioma Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Mesothelioma, M... Mesothelioma; L... Cancer | Apheresis Next Generation... Long Range NGS ... | 18 Years - | A2 Biotherapeutics Inc. | |
| Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma | NCT00566228 | Lymphoma | autologous hema... leukapheresis | 18 Years - 120 Years | Mayo Clinic | |
| Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors | NCT01902771 | Glioma Brain Cancer Brain Tumor Glioblastoma Mu... High Grade Glio... | Dendritic Cell ... Tumor Lysate Imiquimod Leukapheresis | 1 Year - 29 Years | University of Miami | |
| Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer | NCT03240861 | HLA-A*0201 Posi... Locally Advance... NY-ESO-1 Positi... Unresectable Ma... Sarcoma | 18F-FHBG Aldesleukin Busulfan Cellular Therap... Computed Tomogr... Filgrastim Fludarabine Leukapheresis Plerixafor Positron Emissi... | 16 Years - | Jonsson Comprehensive Cancer Center | |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | NCT06343376 | Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent High ... Recurrent Mantl... Recurrent Trans... Recurrent Trans... Refractory Chro... Refractory Diff... Refractory Foll... Refractory High... Refractory Mant... Refractory Tran... Refractory Tran... | Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Echocardiograph... EGFRt/19-28z/IL... Fludarabine Pho... Leukapheresis Multigated Acqu... Positron Emissi... | 18 Years - | Roswell Park Cancer Institute | |
| A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas | NCT05773040 | Lymphomas B-cell Lymphoma... | JV-213 Leukapheresis | 18 Years - | M.D. Anderson Cancer Center | |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma | NCT05801913 | High Grade B-Ce... Intermediate Gr... Recurrent B-Cel... Refractory B-Ce... | Anti-CD19-CAR C... Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Leukapheresis Lymphodepletion... Magnetic Resona... Multi-peptide C... Positron Emissi... X-Ray Imaging | 18 Years - | City of Hope Medical Center | |
| Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer | NCT00968630 | Hematopoietic a... HIV Infection | Laboratory Biom... Leukapheresis | - | Fred Hutchinson Cancer Center | |
| Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells | NCT06186401 | EGFR Gene Mutat... Glioblastoma MGMT-Unmethylat... Recurrent Gliob... | E-SYNC T Cells Cyclophosphamid... Fludarabine (no... Leukapheresis Surgical resect... | 18 Years - | University of California, San Francisco | |
| Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) | NCT02703779 | Multiple Myelom... | Bortezomib Granulocyte col... Mozobil | 18 Years - | University of Kansas Medical Center | |
| Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma | NCT05625594 | Central Nervous... | Aspiration Biospecimen Col... Catheterization CD19CAR-CD28-CD... Computed Tomogr... Cyclophosphamid... Fludarabine Leukapheresis Lumbar Puncture Magnetic Resona... Positron Emissi... | 18 Years - | City of Hope Medical Center | |
| Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine | NCT00861406 | Melanoma | Pegylated Inter... GP-100 Peptide ... | 18 Years - | M.D. Anderson Cancer Center | |
| Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation | NCT00363467 | Acute Myeloid L... | G-CSF Leukapheresis Busulfan Stem cell reinf... | 56 Years - 74 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant | NCT00089453 | Multiple Myelom... | Dexamethasone Cyclophosphamid... Melphalan Fludarabine Bortezomide Leukapheresis Interleukin Infusion #1 Leukapheresis #... Infusion #2 Auto Graft | 18 Years - | University of Arkansas | |
| Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | NCT01413568 | Acute Myeloid L... Adult Acute Lym... Chronic Myeloge... Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... Myelodysplastic... Myeloproliferat... | POL6326 Leukapheresis PBSC Transplant | 18 Years - 75 Years | Polyphor Ltd. | |
| Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer | NCT03532217 | Metastatic Horm... | PROSTVAC-V PROSTVAC-F Nivolumab Ipilimumab Neoantigen DNA ... TriGrid Deliver... Tumor biopsy Peripheral bloo... Fecal samples Leukapheresis | 18 Years - | Washington University School of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
